| Description | McN3716 is a carnitine palmitoyltransferase I (CPT-1) inhibitor for the study of metabolic diseases. |
| In vivo | McN3716（Methyl palmoxirate，MEP）显著抑制大鼠脑线粒体β-氧化，与对照组相比，所有测定的HETE和环氧三烯酸（EET，ARA的非酶自氧化代谢产物）水平下降了23%到44%和32%到50%。值得注意的是，15-HETE的水平未受影响。McN3716处理还显著降低了6-酮-PGF1α（PGI2的副产品）的水平，下降幅度为34%。同样，治疗后大鼠脑中的氢氧化二十碳五烯酸（EPA的非酶自氧化代谢产物）也下降了35%到76%[1]。 |
| Synonyms | NSC359682, Methyl palmoxirate |
| molecular weight | 298.46 |
| Molecular formula | C18H34O3 |
| CAS | 69207-52-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 2.98 mg/mL (10 mM), Sonication is recommended. |
| References | 1. Chen CT, et al. Inhibiting mitochondrial β-oxidation selectively reduces levels of nonenzymatic oxidative polyunsaturated fatty acid metabolites in the brain. J Cereb Blood Flow Metab. 2014 Mar;34(3):376-9. |